

Autosomal-dominant Alzheimer's disease: a review and Alzheimer's disease

Alzheimer's Research and Therapy

3, 1

DOI: [10.1186/alzrt59](https://doi.org/10.1186/alzrt59)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Defining and describing the pre-dementia stages of familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 29.	3.0	11
2	Use of Biomarkers in Clinical Trials of Alzheimer Disease. <i>Molecular Diagnosis and Therapy</i> , 2011, 15, 313-325.	1.6	20
3	Should persons with autosomal dominant AD be included in clinical trials?. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 18.	3.0	2
4	Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview. <i>Neurobiology of Aging</i> , 2011, 32, S1-S3.	1.5	32
5	Testing the Right Target and Right Drug at the Right Stage. <i>Science Translational Medicine</i> , 2011, 3, 111cm33.	5.8	459
6	Intracellular APP Domain Regulates Serine-Palmitoyl-CoA Transferase Expression and Is Affected in Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-8.	1.1	43
7	Combining biomarkers: the future for Alzheimer's disease prevention studies?. <i>Neurodegenerative Disease Management</i> , 2011, 1, 175-178.	1.2	0
8	Current conceptions of the etiology and risk factors for Alzheimer's disease and their possible implications on the design of dementia clinical trials. <i>Clinical Investigation</i> , 2011, 1, 1491-1503.	0.0	0
10	Setting the stage for prevention of familial Alzheimer's disease. <i>Lancet Neurology</i> , The, 2011, 10, 200-201.	4.9	1
11	Alzheimer's Disease: The Challenge of the Second Century. <i>Science Translational Medicine</i> , 2011, 3, 77sr1.	5.8	1,109
12	Alzheimer's Disease Clinical Trials: Changing the Paradigm. <i>Current Psychiatry Reports</i> , 2011, 13, 437-442.	2.1	11
13	Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 321-329.	1.2	309
14	Ethical issues in Alzheimer's disease: an overview. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 557-567.	1.4	20
15	Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. <i>Advances in Pharmacology</i> , 2012, 64, 27-81.	1.2	78
16	Cerebrospinal Fluid Biomarkers and Proximity to Diagnosis in Preclinical Familial Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 1-5.	0.7	38
17	CSF Biomarkers for Secondary Prevention Trials. <i>Archives of Neurology</i> , 2012, 69, 691-2.	4.9	2
18	Cerebrospinal Fluid Biomarkers for Clinical Trials. <i>Archives of Neurology</i> , 2012, 69, 1407.	4.9	2
19	Cerebral microbleeds in familial Alzheimer's disease. <i>Brain</i> , 2012, 135, e201-e201.	3.7	15

#	ARTICLE	IF	CITATIONS
20	Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. <i>Lancet Neurology</i> , The, 2012, 11, 1048-1056.	4.9	450
21	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 795-804.	13.9	3,005
22	The genetics and neuropathology of neurodegenerative disorders: perspectives and implications for research and clinical practice. <i>Acta Neuropathologica</i> , 2012, 124, 297-303.	3.9	12
23	Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 9.	3.0	137
24	Characterizing the Preclinical Stages of Alzheimer's Disease and the Prospect of Presymptomatic Intervention. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S405-S416.	1.2	73
25	Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. <i>Progress in Neurobiology</i> , 2012, 97, 38-51.	2.8	153
26	Preventing Alzheimer's Disease. <i>Science</i> , 2012, 337, 1488-1492.	6.0	328
27	PET amyloid-beta imaging in preclinical Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 370-379.	1.8	132
28	Alzheimer Mechanisms and Therapeutic Strategies. <i>Cell</i> , 2012, 148, 1204-1222.	13.5	1,548
29	When, where, and how does Alzheimer's disease start?. <i>Lancet Neurology</i> , The, 2012, 11, 1017-1018.	4.9	7
30	Brain imaging in the study of Alzheimer's disease. <i>NeuroImage</i> , 2012, 61, 505-516.	2.1	109
31	Recent Alzheimer's disease research highlights. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 14.	3.0	0
32	Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials. <i>PLoS ONE</i> , 2012, 7, e47739.	1.1	62
33	A Highly Sensitive Gold Nanoparticle-Based Assay for Acetylcholinesterase in Cerebrospinal Fluid of Transgenic Mice with Alzheimer's Disease. <i>Advanced Healthcare Materials</i> , 2012, 1, 90-95.	3.9	88
34	Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. <i>Neurodegenerative Disease Management</i> , 2012, 2, 183-195.	1.2	20
35	Ushering in the study and treatment of preclinical Alzheimer disease. <i>Nature Reviews Neurology</i> , 2013, 9, 371-381.	4.9	125
36	Is Alzheimer's disease a homogeneous disease entity?. <i>Journal of Neural Transmission</i> , 2013, 120, 1475-1477.	1.4	6
37	FDG PET in dementia multicenter studies and clinical trials. <i>Clinical and Translational Imaging</i> , 2013, 1, 261-270.	1.1	8

#	ARTICLE	IF	CITATIONS
38	Absence of A673T amyloid- β precursor protein variant in Alzheimer's disease and other neurological diseases. <i>Neurobiology of Aging</i> , 2013, 34, 2441.e7-2441.e8.	1.5	24
40	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. <i>BMC Psychology</i> , 2013, 1, 30.	0.9	153
41	SUMO and Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2013, 15, 720-736.	1.8	82
42	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2013, 125, 201-213.	3.9	103
43	An unbiased longitudinal analysis framework for tracking white matter changes using diffusion tensor imaging with application to Alzheimer's disease. <i>NeuroImage</i> , 2013, 72, 153-163.	2.1	111
44	Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. <i>Revue Neurologique</i> , 2013, 169, 737-743.	0.6	122
45	Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 154-162.	0.9	47
46	The advantages of frontotemporal degeneration drug development (part of frontotemporal) Tj ETQq1 1 0.784314 rgBT / Overlock 10	0.4	48
47	Research and standardization in Alzheimer's trials: Reaching international consensus. , 2013, 9, 160-168.		20
48	Risk and resilience: A new perspective on Alzheimer's disease. <i>Geriatric Mental Health Care</i> , 2013, 1, 47-55.	0.3	4
49	Cerebrospinal fluid biomarkers in Parkinson disease. <i>Nature Reviews Neurology</i> , 2013, 9, 131-140.	4.9	177
50	Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2013, 9, 123.	0.4	100
51	Developing Therapeutic Antibodies for Neurodegenerative Disease. <i>Neurotherapeutics</i> , 2013, 10, 459-472.	2.1	166
53	A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. <i>Progress in Neurobiology</i> , 2013, 110, 114-123.	2.8	26
54	Reply: Implications of presymptomatic change in thalamus and caudate in Alzheimer's disease. <i>Brain</i> , 2013, 136, e259-e259.	3.7	3
55	The pattern of atrophy in familial Alzheimer disease. <i>Neurology</i> , 2013, 81, 1425-1433.	1.5	67
56	Neuroimaging in Neurodegenerative Dementias. <i>Seminars in Neurology</i> , 2013, 32, 347-360.	0.5	17
57	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2013, 81, 736-744.	1.5	174

#	ARTICLE	IF	CITATIONS
58	Clinical, Biological, and Imaging Features of Monogenic Alzheimer's Disease. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	27
59	Neuroimaging Biomarkers of Neurodegenerative Diseases and Dementia. <i>Seminars in Neurology</i> , 2013, 33, 386-416.	0.5	110
60	Increased in Vivo Amyloid- β 42 Production, Exchange, and Loss in Presenilin Mutation Carriers. <i>Science Translational Medicine</i> , 2013, 5, 189ra77.	5.8	196
61	Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. <i>Brain</i> , 2013, 136, 1399-1414.	3.7	174
62	Biomarker-Driven Therapeutic Management of Alzheimer's Disease: Establishing the Foundations. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 95, 67-77.	2.3	19
63	Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 556-561.	0.9	44
64	Serum Multivalent Cationic Pattern: Speculation on the Efficient Approach for Detection of Alzheimer's Disease. <i>Scientific Reports</i> , 2013, 3, 2782.	1.6	16
65	Using Genetics to Enable Studies on the Prevention of Alzheimer's Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 177-185.	2.3	67
66	Aftins Increase Amyloid- β 42, Lower Amyloid- β 38, and Do Not Alter Amyloid- β 40 Extracellular Production in vitro: Toward a Chemical Model of Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 107-120.	1.2	18
67	Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 48.	3.0	115
68	Pupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers. <i>Current Alzheimer Research</i> , 2013, 10, 790-796.	0.7	30
69	Genetic Influences on Atrophy Patterns in Familial Alzheimer's Disease: A Comparison of APP and PSEN1 Mutations. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 199-212.	1.2	36
70	Hereditary and sporadic beta-amyloidoses. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 1202.	3.0	9
71	CSF Biomarkers of Alzheimer's Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. <i>Advances in Geriatrics</i> , 2014, 2014, 1-14.	1.6	15
72	Altered Proteolysis in Fibroblasts of Alzheimer Patients with Predictive Implications for Subjects at Risk of Disease. <i>International Journal of Alzheimer's Disease</i> , 2014, 2014, 1-8.	1.1	18
73	Combination and current concepts as well as future strategies for the treatment of Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 439.	1.0	30
74	Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease. <i>Science Translational Medicine</i> , 2014, 6, 226ra30.	5.8	320
75	Community Engagement in Diverse Populations for Alzheimer Disease Prevention Trials. <i>Alzheimer Disease and Associated Disorders</i> , 2014, 28, 269-274.	0.6	21

#	ARTICLE	IF	CITATIONS
76	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1111.	4.5	112
77	The neuropsychology of normal aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 84-92.	0.4	55
78	A novel presenilin 1 mutation (Ala275Val) as cause of early-onset familial Alzheimer disease. <i>Neuroscience Letters</i> , 2014, 566, 115-119.	1.0	7
79	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , The, 2014, 13, 614-629.	4.9	2,657
80	Autosomalâ€dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter A β production. <i>Journal of Neurochemistry</i> , 2014, 128, 330-339.	2.1	33
81	Reliability and usability of an internet-based computerized cognitive testing battery in community-dwelling older people. <i>Computers in Human Behavior</i> , 2014, 30, 199-205.	5.1	35
82	Alzheimerâ€™s Disease, Anesthesia, and Surgery: A Clinically Focused Review. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014, 28, 1609-1623.	0.6	39
83	Justifying reimbursement for Alzheimer's diagnostics and treatments: Seeking alignment on evidence. , 2014, 10, 503-508.		6
84	Alzheimerâ€™s Disease Genetics: From the Bench to the Clinic. <i>Neuron</i> , 2014, 83, 11-26.	3.8	396
85	Symptom onset in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2014, 83, 253-260.	1.5	391
86	Alzheimer's Disease prevalence, costs, and prevention for military personnel and veterans. <i>Alzheimer's and Dementia</i> , 2014, 10, S105-10.	0.4	56
87	Progress Update: Fluid and Imaging Biomarkers in Alzheimerâ€™s Disease. <i>Biological Psychiatry</i> , 2014, 75, 520-526.	0.7	22
88	Early astrocytosis in autosomal dominant Alzheimerâ€™s disease measured in vivo by multi-tracer positron emission tomography. <i>Scientific Reports</i> , 2015, 5, 16404.	1.6	110
89	Biomarkers in Sporadic and Familial Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 291-317.	1.2	75
90	Sensitivity of Neuropsychological Tests to Identify Cognitive Decline in Highly Educated Elderly Individuals: 12 Months Follow up. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 607-616.	1.2	21
91	Diffusion imaging changes in grey matter in Alzheimerâ€™s disease: a potential marker of early neurodegeneration. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 47.	3.0	132
92	Predictive Testing for Alzheimerâ€™s Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 252-254.	0.6	15
93	Alzheimerâ€™s Disease: Mechanism and Approach to Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 26417-26451.	1.8	82

#	ARTICLE	IF	CITATIONS
94	Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. <i>Frontiers in Neurology</i> , 2015, 6, 142.	1.1	25
95	A molecular toolbox for genetic manipulation of zebrafish. <i>Advances in Genomics and Genetics</i> , 0, , 151.	0.8	31
96	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560.	0.4	205
97	Voices from the field: Expert reflections on mild cognitive impairment. <i>Dementia</i> , 2015, 14, 285-297.	1.0	9
98	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 412-419.	1.2	80
99	The English (H6R) familial Alzheimer's disease mutation facilitates zinc-induced dimerization of the amyloid- β metal-binding domain. <i>Metallomics</i> , 2015, 7, 422-425.	1.0	38
100	Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 339-348.	1.5	68
101	Novel presenilin 1 mutation (p.I83T) in Tunisian family with early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2904.e9-2904.e11.	1.5	8
102	Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. <i>Neuropeptides</i> , 2015, 52, 1-18.	0.9	405
103	Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 792-814.	0.4	241
104	Alzheimer's disease research in the context of the national plan to address Alzheimer's disease. <i>Molecular Aspects of Medicine</i> , 2015, 43-44, 16-24.	2.7	14
105	Advances in the prevention of Alzheimer's Disease. <i>F1000prime Reports</i> , 2015, 7, 50.	5.9	72
106	Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 912.	4.5	94
107	Alzheimer's Disease and the Search for Environmental Risk Factors. , 2015, , 315-327.		0
108	Alzheimer's Disease and Mechanism-Based Attempts to Enhance Cognition. , 2015, , 193-231.		0
109	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 3140-3151.	1.5	53
110	Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2015, 5, 425-443.	1.2	28
111	Is dominantly inherited Alzheimer disease a clone of sporadic Alzheimer disease?. <i>Neurology</i> , 2015, 85, 750-751.	1.5	2

#	ARTICLE	IF	CITATIONS
112	Effects of changing from non-accelerated to accelerated MRI for follow-up in brain atrophy measurement. <i>NeuroImage</i> , 2015, 107, 46-53.	2.1	20
113	Innovative diagnostic tools for early detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 561-578.	0.4	213
114	Stem Cell Therapy: A Prospective Treatment for Alzheimer's Disease. <i>Psychiatry Investigation</i> , 2016, 13, 583.	0.7	25
115	Peripheral Vitamin C Levels in Alzheimer's Disease: A Cross-Sectional Study. <i>Journal of Nutritional Science and Vitaminology</i> , 2016, 62, 432-436.	0.2	9
116	Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. <i>Science Translational Medicine</i> , 2016, 8, 369ra178.	5.8	211
117	Specific Triazine Herbicides Induce Amyloid- β 242 Production. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1593-1605.	1.2	14
118	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. <i>Neurobiology of Aging</i> , 2016, 39, 99-107.	1.5	34
119	Dementias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 138, 123-151.	1.0	35
120	Localization of zinc binding sites of Ab1-16 with English mutation during formation of monomers and dimers with zinc. <i>International Journal of Mass Spectrometry</i> , 2016, 409, 67-72.	0.7	3
121	Presymptomatic cortical thinning in familial Alzheimer disease. <i>Neurology</i> , 2016, 87, 2050-2057.	1.5	58
122	Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 29078.	1.6	39
123	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). <i>Lancet Neurology</i> , The, 2016, 15, 1317-1325.	4.9	87
124	Blood-Brain Barrier Transport of Alzheimer's Amyloid β -Peptide. , 2016, , 251-270.		5
125	Alzheimer's Disease Therapeutics Targeting Apolipoprotein E. , 2016, , 271-303.		0
126	High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β -amyloid peptide. <i>Biochemical Journal</i> , 2016, 473, 1563-1578.	1.7	29
127	Diverging longitudinal changes in astrogliosis and amyloid PET in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2016, 139, 922-936.	3.7	235
128	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. <i>Alzheimer's and Dementia</i> , 2016, 12, 614-622.	0.4	42
129	CAP-advancing the evaluation of preclinical Alzheimer disease treatments. <i>Nature Reviews Neurology</i> , 2016, 12, 56-61.	4.9	80

#	ARTICLE	IF	CITATIONS
130	Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective. <i>Molecular Neurobiology</i> , 2016, 53, 4833-4864.	1.9	52
131	Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid- β^2 and other amyloidogenic proteins. <i>Journal of Lipid Research</i> , 2017, 58, 824-836.	2.0	159
132	Emerging amyloid and tau targeting treatments for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 697-711.	1.4	11
133	Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 683-695.	1.4	34
134	Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 1-9.	1.2	49
135	PE859, A Novel Curcumin Derivative, Inhibits Amyloid- β^2 and Tau Aggregation, and Ameliorates Cognitive Dysfunction in Senescence-Accelerated Mouse Prone 8. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 313-328.	1.2	39
136	Risk factors associated with the onset and progression of Alzheimer's disease: A systematic review of the evidence. <i>NeuroToxicology</i> , 2017, 61, 143-187.	1.4	230
137	The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 327-334.	1.2	8
138	Inflammasomes as therapeutic targets for Alzheimer's disease. <i>Brain Pathology</i> , 2017, 27, 223-234.	2.1	110
139	Serum neurofilament light in familial Alzheimer disease. <i>Neurology</i> , 2017, 89, 2167-2175.	1.5	204
140	The DIAN Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. <i>Alzheimer's and Dementia</i> , 2017, 13, 8-19.	0.4	230
141	Data-Driven Sequence of Changes to Anatomical Brain Connectivity in Sporadic Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 580.	1.1	42
142	Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-APP ^{Swe} Mice Without Inducing Microhemorrhage. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1393-1413.	1.2	24
143	Molecular Mechanisms of Synaptic Plasticity and Memory and Their Dysfunction in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 65-135.		1
144	Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease. <i>Molecules and Cells</i> , 2017, 40, 613-620.	1.0	131
145	Phenotypic Variability in Autosomal Dominant Familial Alzheimer Disease due to the S170F Mutation of Presenilin-1. <i>Neurodegenerative Diseases</i> , 2018, 18, 57-68.	0.8	5
146	Induction of Amyloid- β^2 Production by Fipronil and Other Pyrazole Insecticides. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1663-1681.	1.2	23
147	Functional and structural connectome properties in the 5XFAD transgenic mouse model of Alzheimer's disease. <i>Network Neuroscience</i> , 2018, 2, 241-258.	1.4	23

#	ARTICLE	IF	CITATIONS
148	Proximity to Parental Symptom Onset and Amyloid- β Burden in Sporadic Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 608.	4.5	19
149	Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2018, 17, 123-132.	4.9	84
150	Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2018, 378, 321-330.	13.9	795
151	Regional association of pCASL-MRI with FDG-PET and PiB-PET in people at risk for autosomal dominant Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018, 17, 751-760.	1.4	27
152	Resting-state connectivity in neurodegenerative disorders: Is there potential for an imaging biomarker?. <i>NeuroImage: Clinical</i> , 2018, 18, 849-870.	1.4	186
153	Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. <i>Alzheimer's and Dementia</i> , 2018, 14, 743-750.	0.4	51
154	Data-driven models of dominantly-inherited Alzheimer's disease progression. <i>Brain</i> , 2018, 141, 1529-1544.	3.7	111
155	The cerebellum in Alzheimer's disease: evaluating its role in cognitive decline. <i>Brain</i> , 2018, 141, 37-47.	3.7	222
156	Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome. <i>Free Radical Biology and Medicine</i> , 2018, 114, 52-61.	1.3	56
157	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 25-35.	1.4	34
158	Alzheimer's disease. <i>European Journal of Neurology</i> , 2018, 25, 59-70.	1.7	1,624
159	Estimating diagnostic accuracy for clustered ordinal diagnostic groups in the three-class case—Application to the early diagnosis of Alzheimer disease. <i>Statistical Methods in Medical Research</i> , 2018, 27, 701-714.	0.7	2
160	A Novel Method for Identifying Alzheimer's Disease-related Proteins. , 2018, , .		0
161	A β ₄₂ /A β ₄₀ Ratios of Presenilin 1 Mutations Correlate with Clinical Onset of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 939-945.	1.2	37
162	The relevance of cerebrospinal fluid β -synuclein levels to sporadic and familial Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 130.	2.4	44
163	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 669-677.	1.2	14
164	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 113.	3.0	54
165	Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease —conformist, nonconformist, and realistic prospects for AD pathogenesis. <i>Translational Neurodegeneration</i> , 2018, 7, 34.	3.6	77

#	ARTICLE	IF	CITATIONS
166	The impact of amyloid β and tau on prospective cognitive decline in older individuals. <i>Annals of Neurology</i> , 2019, 85, 181-193.	2.8	171
167	Next-generation biomarker discovery in Alzheimer's disease using metabolomics "from animal to human studies. <i>Bioanalysis</i> , 2018, 10, 1525-1546.	0.6	27
168	Natural Peptides in Drug Discovery Targeting Acetylcholinesterase. <i>Molecules</i> , 2018, 23, 2344.	1.7	35
169	Healthy Aging and Dementia: Two Roads Diverging in Midlife?. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 275.	1.7	78
170	A novel cognitive disease progression model for clinical trials in autosomal β -dominant Alzheimer's disease. <i>Statistics in Medicine</i> , 2018, 37, 3047-3055.	0.8	31
171	Diagnostic utility of ¹⁸ F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1487-1496.	3.3	35
172	Altered Processing of β -Amyloid in SH-SY5Y Cells Induced by Model Senescent Microglia. <i>ACS Chemical Neuroscience</i> , 2018, 9, 3137-3152.	1.7	25
173	Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 69.	3.0	22
174	Amyloid- β Plaques in Clinical Alzheimer's Disease Brain Incorporate Stable Isotope Tracer In Vivo and Exhibit Nanoscale Heterogeneity. <i>Frontiers in Neurology</i> , 2018, 9, 169.	1.1	24
175	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. <i>Frontiers in Neuroscience</i> , 2018, 12, 37.	1.4	132
176	ABCA7 and Pathogenic Pathways of Alzheimer's Disease. <i>Brain Sciences</i> , 2018, 8, 27.	1.1	87
177	Effect of <i>BDNF</i> Val66Met on disease markers in dominantly inherited Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 84, 424-435.	2.8	25
178	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 45.	3.0	11
179	Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model. <i>Nature Communications</i> , 2019, 10, 3758.	5.8	478
180	Ghrelin in Alzheimer's disease: Pathologic roles and therapeutic implications. <i>Ageing Research Reviews</i> , 2019, 55, 100945.	5.0	34
181	Beneficial Effects of Fingolimod in Alzheimer's Disease: Molecular Mechanisms and Therapeutic Potential. <i>NeuroMolecular Medicine</i> , 2019, 21, 227-238.	1.8	28
182	Association of Lifestyle and Genetic Risk With Incidence of Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 430.	3.8	421
183	Dopa Responsive Parkinsonism in an Early Onset Alzheimer's Disease Patient with a Presenilin 1 Mutation (A434T). <i>Journal of Alzheimer's Disease</i> , 2019, 71, 7-13.	1.2	7

#	ARTICLE	IF	CITATIONS
184	Lessons Learned From Public Private Partnerships and Consortia: The ADNI Paradigm. Handbook of Behavioral Neuroscience, 2019, , 239-246.	0.7	0
185	Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis. Developmental Neurobiology, 2019, 79, 716-737.	1.5	30
186	Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET. Japanese Journal of Radiology, 2019, 37, 735-749.	1.0	35
187	Cerebral Amyloid Angiopathy, Alzheimer's Disease and MicroRNA: miRNA as Diagnostic Biomarkers and Potential Therapeutic Targets. NeuroMolecular Medicine, 2019, 21, 369-390.	1.8	18
188	Identification of a rare presenilin 1 single amino acid deletion mutation (F175del) with unusual amyloid- β processing effects. Neurobiology of Aging, 2019, 84, 241.e5-241.e11.	1.5	9
189	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nature Medicine, 2019, 25, 277-283.	15.2	610
190	Computing the Pathogenicity of Alzheimer's Disease Presenilin 1 Mutations. Journal of Chemical Information and Modeling, 2019, 59, 858-870.	2.5	19
191	A mixed-methods study of cultural beliefs about dementia and genetic testing among Mexicans and Mexican-Americans at risk for autosomal dominant Alzheimer's disease. Journal of Genetic Counseling, 2019, 28, 921-932.	0.9	12
192	Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses. Frontiers in Neuroscience, 2019, 13, 446.	1.4	122
193	Regional patterns of 18F-florbetaben uptake in presenilin 1 mutation carriers. Neurobiology of Aging, 2019, 81, 1-8.	1.5	5
194	Binding between Prion Protein and A β Oligomers Contributes to the Pathogenesis of Alzheimer's Disease. Virologica Sinica, 2019, 34, 475-488.	1.2	10
196	Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease. Frontiers in Pharmacology, 2019, 10, 189.	1.6	13
197	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. Brain, 2019, 142, 1429-1440.	3.7	36
198	Nanoscale structure of amyloid- β plaques in Alzheimer's disease. Scientific Reports, 2019, 9, 5181.	1.6	52
199	Alzheimer's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 231-255.	1.0	415
200	<p>Alzheimer's Disease " Why We Need Early Diagnosis</p>. Degenerative Neurological and Neuromuscular Disease, 2019, Volume 9, 123-130.	0.7	181
201	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nature Neuroscience, 2019, 22, 1903-1912.	7.1	242
202	Radiogenomics for Precision Medicine With a Big Data Analytics Perspective. IEEE Journal of Biomedical and Health Informatics, 2019, 23, 2063-2079.	3.9	34

#	ARTICLE	IF	CITATIONS
203	The metalloprotease ADAMTS4 generates N-truncated A β 42 species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 239-257.	3.9	44
204	Blood-Brain Barrier: From Physiology to Disease and Back. <i>Physiological Reviews</i> , 2019, 99, 21-78.	13.1	1,232
205	Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 60-68.	1.3	4
206	The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. <i>Alzheimer's and Dementia</i> , 2020, 16, 1553-1560.	0.4	165
207	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. <i>Information Fusion</i> , 2020, 58, 153-167.	11.7	17
208	Biomarkers of Alzheimer Disease. <i>journal of applied laboratory medicine, The</i> , 2020, 5, 194-208.	0.6	29
209	Therapeutic implications of circadian clocks in neurodegenerative diseases. <i>Journal of Neuroscience Research</i> , 2020, 98, 1095-1113.	1.3	10
210	Differential Profile of Systemic Extracellular Vesicles From Sporadic and Familial Alzheimer's Disease Leads to Neuroglial and Endothelial Cell Degeneration. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 587989.	1.7	16
211	From beta amyloid to altered proteostasis in Alzheimer's disease. <i>Ageing Research Reviews</i> , 2020, 64, 101126.	5.0	31
212	An automated clinical mass spectrometric method for identification and quantification of variant and wild-type amyloid β 1-40 and 1-42 peptides in CSF. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12036.		5
213	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102491.	1.4	17
214	Late-onset vs nonmendelian early-onset Alzheimer disease. <i>Neurology: Genetics</i> , 2020, 6, e512.	0.9	82
215	Genetic counselling and testing for inherited dementia: single-centre evaluation of the consensus Italian DIAfN protocol. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 152.	3.0	7
216	Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NiAD) study at baseline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12096.	1.8	15
217	Microglia Do Not Take Up Soluble Amyloid-beta Peptides, But Partially Degrade Them by Secreting Insulin-degrading Enzyme. <i>Neuroscience</i> , 2020, 443, 30-43.	1.1	14
218	Role of environmental pollutants in Alzheimer's disease: a review. <i>Environmental Science and Pollution Research</i> , 2020, 27, 44724-44742.	2.7	40
219	Statistical Disease Progression Modeling in Alzheimer Disease. <i>Frontiers in Big Data</i> , 2020, 3, 24.	1.8	33
220	Exploring Beyond the DNA Sequence: A Review of Epigenomic Studies of DNA and Histone Modifications in Dementia. <i>Current Genetic Medicine Reports</i> , 2020, 8, 79-92.	1.9	12

#	ARTICLE	IF	CITATIONS
221	Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimer's disease: a retrospective cohort analysis. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 126.	3.0	13
222	Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 112.	3.0	18
223	Analyses Mutations in GSN, CST3, TTR, and ITM2B Genes in Chinese Patients With Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 581524.	1.7	5
224	Î³-Secretase Modulatory Proteins: The Guiding Hand Behind the Running Scissors. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 614690.	1.7	12
225	Mutational analysis in familial Alzheimer's disease of Han Chinese in Taiwan with a predominant mutation PSEN1 p.Met146Ile. <i>Scientific Reports</i> , 2020, 10, 19769.	1.6	7
226	Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review. <i>Frontiers in Endocrinology</i> , 2020, 11, 560375.	1.5	39
227	Machine Learning Classification Identifies Cerebellar Contributions to Early and Moderate Cognitive Decline in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 524024.	1.7	7
228	Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimer's Disease. <i>Brain Sciences</i> , 2020, 10, 815.	1.1	6
229	Fluid Biomarkers and APOE Status of Early Onset Alzheimer's Disease Variants: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 827-843.	1.2	4
230	Combination Drug Therapy for the Management of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3272.	1.8	110
231	Further understanding the connection between Alzheimer's disease and Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, 1065-1077.	0.4	52
232	Towards a Redefinition of Cognitive Frailty. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 831-843.	1.2	27
233	Hemizygous mutations in L1CAM in two unrelated male probands with childhood onset psychosis. <i>Psychiatric Genetics</i> , 2020, 30, 73-82.	0.6	2
234	Contributions of DNA Damage to Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1666.	1.8	60
235	Anti-Alzheimer's disease activity of secondary metabolites from <i>Xanthoceras sorbifolia</i> Bunge. <i>Food and Function</i> , 2020, 11, 2067-2079.	2.1	10
236	MRI-based biomarkers of accelerated aging and dementia risk in midlife: how close are we?. <i>Ageing Research Reviews</i> , 2020, 61, 101075.	5.0	24
237	Traditional Chinese Medicine: Role in Reducing Î²-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2020, 11, 497.	1.6	64
238	Cortical microstructural correlates of astrogliosis in autosomal-dominant Alzheimer disease. <i>Neurology</i> , 2020, 94, e2026-e2036.	1.5	42

#	ARTICLE	IF	CITATIONS
239	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 614-628.	4.1	61
240	Proteasome Subunits Involved in Neurodegenerative Diseases. <i>Archives of Medical Research</i> , 2021, 52, 1-14.	1.5	20
241	Sigma ligands as potent inhibitors of A β 2 and A β 2Os in neurons and promising therapeutic agents of Alzheimer's disease. <i>Neuropharmacology</i> , 2021, 190, 108342.	2.0	8
242	Dominantly inherited Alzheimer's disease in Latin America: Genetic heterogeneity and clinical phenotypes. <i>Alzheimer's and Dementia</i> , 2021, 17, 653-664.	0.4	14
243	Psychosis in a Middle-aged Woman. <i>Neurology: Clinical Practice</i> , 2021, 11, e573-e575.	0.8	1
244	Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. <i>Alzheimer's and Dementia</i> , 2021, 17, 271-292.	0.4	25
245	Regenerative nanomedicine applications for neurodegenerative diseases of central nervous system. , 2021, , 259-287.		1
246	Novel Phosphorylation-State Specific Antibodies Reveal Differential Deposition of Ser26 Phosphorylated A β 2 Species in a Mouse Model of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 619639.	1.4	7
247	Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer's disease. <i>Clinical Science</i> , 2021, 135, 109-126.	1.8	32
248	Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. , 2021, , 367-412.		0
249	Cholinergic neurodegeneration in Alzheimer disease mouse models. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 182, 191-209.	1.0	12
250	Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 293.	4.5	57
251	Inflammation, Nitro-Oxidative Stress, Impaired Autophagy, and Insulin Resistance as a Mechanistic Convergence Between Arterial Stiffness and Alzheimer's Disease. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 651215.	1.6	16
252	Phosphoinositides: Roles in the Development of Microglial-Mediated Neuroinflammation and Neurodegeneration. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 652593.	1.8	13
253	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. <i>Brain</i> , 2021, 144, 2176-2185.	3.7	66
254	The Dose-Dependent Pleiotropic Effects of the UBB+1 Ubiquitin Mutant. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 650730.	1.6	2
255	Physical Exercise and Alzheimer's Disease: Effects on Pathophysiological Molecular Pathways of the Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2897.	1.8	30
256	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. <i>Brain Connectivity</i> , 2021, 11, 239-249.	0.8	18

#	ARTICLE	IF	CITATIONS
257	Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. <i>Biomolecules</i> , 2021, 11, 600.	1.8	16
258	Impacts of Iron Metabolism Dysregulation on Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1439-1450.	1.2	10
259	Genetic effect of <i>MTHFR</i> C677T, A1298C, and A1793G polymorphisms on the age at onset, plasma homocysteine, and white matter lesions in Alzheimer's disease in the Chinese population. <i>Aging</i> , 2021, 13, 11352-11362.	1.4	7
260	Alzheimer's Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease. <i>Current Neuropharmacology</i> , 2021, 19, 498-512.	1.4	16
261	White matter microstructure associations with episodic memory in adults with Down syndrome: a tract-based spatial statistics study. <i>Journal of Neurodevelopmental Disorders</i> , 2021, 13, 17.	1.5	9
262	Generation of a gene-corrected human isogenic iPSC line from an Alzheimer's disease iPSC line carrying the London mutation in APP (V717I). <i>Stem Cell Research</i> , 2021, 53, 102373.	0.3	2
263	Calcium Dyshomeostasis in Alzheimer's Disease Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4914.	1.8	76
264	PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 624330.	1.7	39
265	Association of <i>HMOX1</i> with sporadic Alzheimer's disease in southern Han Chinese. <i>European Journal of Neurology</i> , 2021, 28, 2922-2926.	1.7	2
266	Understanding familial Alzheimer's disease: The fit-to-stay mechanism of β -secretase. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2022, 12, e1556.	6.2	8
267	Machine learning and deep learning algorithms used to diagnosis of Alzheimer's: Review. <i>Materials Today: Proceedings</i> , 2021, 47, 5151-5156.	0.9	7
269	Biomarkers for neurodegenerative diseases. <i>Nature Medicine</i> , 2021, 27, 954-963.	15.2	399
270	Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6355.	1.8	74
271	Human Monocytes Plasticity in Neurodegeneration. <i>Biomedicines</i> , 2021, 9, 717.	1.4	5
272	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
273	The informed road map to prevention of Alzheimer Disease: A call to arms. <i>Molecular Neurodegeneration</i> , 2021, 16, 49.	4.4	43
274	Comparing amyloid- β^2 plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , 2021, 142, 689-706.	3.9	15
275	The human connectome in Alzheimer disease - relationship to biomarkers and genetics. <i>Nature Reviews Neurology</i> , 2021, 17, 545-563.	4.9	106

#	ARTICLE	IF	CITATIONS
276	Global Cardiovascular Risk Profile and Cerebrovascular Abnormalities in Presymptomatic Individuals with CADASIL or Autosomal Dominant Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 841-853.	1.2	2
278	Dominantly inherited Alzheimer's disease: a compass for drug development. <i>Nature Medicine</i> , 2021, 27, 1148-1150.	15.2	3
279	Variability in the type and layer distribution of cortical A β pathology in familial Alzheimer's disease. <i>Brain Pathology</i> , 2022, 32, e13009.	2.1	12
280	Blood Biomarkers for Alzheimer's Disease in Down Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3639.	1.0	17
281	Different Sides of Depression in the Elderly: An In-depth View on the Role of A β Peptides. <i>Current Medicinal Chemistry</i> , 2022, 29, 5731-5757.	1.2	7
282	Prominent Striatum Amyloid Retention in Early-Onset Familial Alzheimer's Disease With PSEN1 Mutations: A Pilot PET/MR Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 732159.	1.7	3
283	A Case of Early-Onset Alzheimer's Disease Mimicking Schizophrenia in a Patient with Presenilin 1 Mutation (S170P). <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1025-1031.	1.2	1
284	Mild Cognitive Impairment and Dementia Reported by Former Professional Football Players over 50 yr of Age: An NFL-LONG Study. <i>Medicine and Science in Sports and Exercise</i> , 2022, 54, 424-431.	0.2	19
285	Effects of ApoE genotype on clinical phenotypes in early-onset and late-onset Alzheimer's disease in China: Data from the PUMCH dementia cohort. <i>Brain and Behavior</i> , 2021, 11, e2373.	1.0	6
286	Modeling autosomal dominant Alzheimer's disease with machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, 1005-1016.	0.4	12
287	Early-Onset Alzheimer's Disease: What Is Missing in Research?. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 4.	2.0	88
288	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine learning. <i>Alzheimer's and Dementia</i> , 2020, 16, 501-511.	0.4	47
289	Iron Pathophysiology in Alzheimer's Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1173, 67-104.	0.8	40
293	Machine Learning Techniques for the Diagnosis of Alzheimer's Disease. <i>ACM Transactions on Multimedia Computing, Communications and Applications</i> , 2020, 16, 1-35.	3.0	128
294	Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials. <i>PLoS ONE</i> , 2013, 8, e58816.	1.1	38
295	ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE. <i>Journal of prevention of Alzheimer's disease</i> , The, 2015, 2, 1-8.	1.5	35
296	Identification of molecular correlations of RBM8A with autophagy in Alzheimer's disease. <i>Aging</i> , 2019, 11, 11673-11685.	1.4	43
297	Imaging Epigenetics in Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2013, 19, 6393-6415.	0.9	33

#	ARTICLE	IF	CITATIONS
298	Clinical, Genetic, and Neuroimaging Features of Early Onset Alzheimer Disease: The Challenges of Diagnosis and Treatment. <i>Current Alzheimer Research</i> , 2014, 11, 909-917.	0.7	14
299	Neuroprotective Effects of Coffee Bioactive Compounds: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 107.	1.8	97
300	The Potential Role of Epigenetics in Alzheimer's Disease Etiology. <i>Biological Systems, Open Access</i> , 2012, 02, .	0.1	3
301	Pin1 Protects Against Alzheimer's Disease: One Goal, Multiple Mechanisms. , 0, , .		2
302	Alzheimer's Disease and Hyperglycemia: Role of the Insulin Signaling Pathway and GSK-3 Inhibition in Paving a Path to Dementia. <i>Cureus</i> , 2020, 12, e6885.	0.2	10
303	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services" part 2 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 169.	3.0	35
304	Selenomethionine Improves Mitochondrial Function by Upregulating Mitochondrial Selenoprotein in a Model of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 750921.	1.7	7
305	Hypoxia-Induced Neuroinflammation in Alzheimer's Disease: Potential Neuroprotective Effects of <i>Centella asiatica</i> . <i>Frontiers in Physiology</i> , 2021, 12, 712317.	1.3	19
306	The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 4582.	1.0	9
307	Future Perspectives of Alzheimer Disease Research. <i>Trends in the Sciences</i> , 2011, 16, 57-61.	0.0	0
309	Dementia and Bioethics. <i>Mental Health and Illness Worldwide</i> , 2016, , 1-13.	0.1	0
310	Dementia and Bioethics. <i>Mental Health and Illness Worldwide</i> , 2017, , 141-153.	0.1	0
314	Psychiatric Disorders in Alzheimer Disease With the Presenilin-1 L226F Mutation. <i>Cognitive and Behavioral Neurology</i> , 2020, 33, 278-282.	0.5	5
315	Advances in designs for Alzheimer's disease clinical trials. <i>American Journal of Neurodegenerative Disease</i> , 2012, 1, 205-16.	0.1	26
316	Huntington's disease: the past, present, and future search for disease modifiers. <i>Yale Journal of Biology and Medicine</i> , 2013, 86, 217-33.	0.2	31
319	Environmental Substances Associated with Alzheimer's Disease" A Scoping Review. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11839.	1.2	10
320	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2022, 23, 53-66.	4.9	203
321	Zinc Finger Proteins in Neuro-Related Diseases Progression. <i>Frontiers in Neuroscience</i> , 2021, 15, 760567.	1.4	32

#	ARTICLE	IF	CITATIONS
322	Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1754-1764.	0.4	4
323	Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia. <i>Journal of prevention of Alzheimer's disease, The</i> , 2022, 9, 338-347.	1.5	3
324	Gender Differences in Demographic and Pharmacological Factors in Patients Diagnosed with Late-Onset of Alzheimer's Disease. <i>Brain Sciences</i> , 2022, 12, 160.	1.1	4
325	Traditional East Asian Herbal Medicine Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Pharmaceuticals</i> , 2022, 15, 174.	1.7	7
326	Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 112, 39-54.	1.5	49
327	Aetiology and pathophysiology of neurodegenerative disorders. , 2022, , 1-16.		0
328	Age of Symptom Onset and Longitudinal Course of Sporadic Alzheimer's Disease, Frontotemporal Dementia, and Vascular Dementia: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1819-1833.	1.2	5
329	Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2011.	1.8	22
330	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 2687-2698.	0.4	13
331	Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age. <i>Biomolecules</i> , 2022, 12, 371.	1.8	59
332	Circular RNA detection identifies circPSEN1 alterations in brain specific to autosomal dominant Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2022, 10, 29.	2.4	11
333	Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2022, Volume 12, 31-59.	0.7	11
334	Structural basis of Alzheimer's amyloid peptide recognition by engineered lipocalin proteins with aggregation-blocking activity. <i>Biological Chemistry</i> , 2022, 403, 557-571.	1.2	2
335	Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease. <i>Recent Patents on Biotechnology</i> , 2022, 16, 102-121.	0.4	13
336	Psychological Impact of Predictive Genetic Testing for Inherited Alzheimer Disease and Frontotemporal Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2022, Publish Ahead of Print, .	0.6	3
337	Alzheimer's disease "the journey of a healthy brain into organ failure. <i>Molecular Neurodegeneration</i> , 2022, 17, 18.	4.4	41
338	Dementia classification using MR imaging and clinical data with voting based machine learning models. <i>Multimedia Tools and Applications</i> , 2022, 81, 25971-25992.	2.6	13
339	Dissecting the clinical heterogeneity of early-onset Alzheimer's disease. <i>Molecular Psychiatry</i> , 2022, 27, 2674-2688.	4.1	40

#	ARTICLE	IF	CITATIONS
340	Biomarker clustering in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 274-284.	0.4	2
341	Emergence of distinct and heterogeneous strains of amyloid beta with advanced Alzheimer's disease pathology in Down syndrome. <i>Acta Neuropathologica Communications</i> , 2021, 9, 201.	2.4	11
342	COVID-19 in structure of risk factors for cognitive impairment, methods of correction. <i>Medical Alphabet</i> , 2022, , 23-28.	0.0	0
343	Clinical and Molecular Findings in a Turkish Family Who Had a (c.869-1G>A) Splicing Variant in PSEN1 Gene with A Rare Condition: The Variant Alzheimer's Disease with Spastic Paraparesis. <i>Current Alzheimer Research</i> , 2022, 19, 223-235.	0.7	3
344	Differentiating amyloid beta spread in autosomal dominant and sporadic Alzheimer's disease. <i>Brain Communications</i> , 2022, 4, .	1.5	4
345	The relationship of early- and late-onset Alzheimer's disease genes with COVID-19. <i>Journal of Neural Transmission</i> , 2022, 129, 847-859.	1.4	10
375	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.4	2
376	Early memory deficits and extensive brain network disorganization in the App/MAPT double knock-in mouse model of familial Alzheimer's disease. <i>Aging Brain</i> , 2022, 2, 100042.	0.7	5
377	Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
378	Phosphorylated Tau 181 Serum Levels Predict Alzheimer's Disease in the Preclinical Stage. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	6
379	Molecular PET Imaging in Alzheimer's Disease. <i>Journal of Medical and Biological Engineering</i> , 2022, 42, 301-317.	1.0	6
380	Neuropharmacology of Organoselenium Compounds in Mental Disorders and Degenerative Diseases. <i>Current Medicinal Chemistry</i> , 2023, 30, 2357-2395.	1.2	12
381	Neurovascular Dysfunction in Diverse Communities With Health Disparities—Contributions to Dementia and Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	6
382	Possible Neuropathology of Sleep Disturbance Linking to Alzheimer's Disease: Astrocytic and Microglial Roles. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	1.8	9
383	Using SVM for Alzheimer's Disease detection from 3D T1MRI. , 2022, , .		2
384	Pathology and Neuron-Glia Interactions: A Synaptocentric View. <i>Neurochemical Research</i> , 2023, 48, 1026-1046.	1.6	12
385	Covariance-based vs. correlation-based functional connectivity dissociates healthy aging from Alzheimer disease. <i>NeuroImage</i> , 2022, 261, 119511.	2.1	10
386	Gliovascular alterations in sporadic and familial Alzheimer's disease: APOE3 Christchurch homozygote glioprotection. <i>Brain Pathology</i> , 0, , .	2.1	1

#	ARTICLE	IF	CITATIONS
387	Clinical characteristics and genotype-phenotype correlation analysis of familial Alzheimer's disease patients with pathogenic/likely pathogenic amyloid protein precursor mutations. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	2
388	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets. <i>Biomolecules</i> , 2022, 12, 1676.	1.8	24
389	Dementia Prevention in Clinical Practice. <i>Seminars in Neurology</i> , 2022, 42, 525-548.	0.5	8
391	Oligomer Formation by Amyloid- β 242 in a Membrane-Mimicking Environment in Alzheimer's Disease. <i>Molecules</i> , 2022, 27, 8804.	1.7	5
392	Alzheimer's Disease: Clinical Trials and the Amyloid Hypothesis. <i>Annals of the Academy of Medicine, Singapore</i> , 2011, 40, 304-306.	0.2	2
393	Alzheimer's disease and synapse Loss: What can we learn from induced pluripotent stem Cells?. <i>Journal of Advanced Research</i> , 2023, 54, 105-118.	4.4	5
394	Plasma biomarker profiles in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2023, 146, 1132-1140.	3.7	19
395	The microglial immunoreceptor tyrosine-based motif-Syk signaling pathway is a promising target of immunotherapy for Alzheimer's disease. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	1
396	Healthy Aging: Perseverance to well being. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2023, 23, .	0.6	0
397	Clinical and genetic characteristics in a central-southern Chinese cohort of early-onset Alzheimer's disease. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	0
398	Clinical Management in Alzheimer's Disease in the Era of Disease-Modifying Therapies. <i>Current Treatment Options in Neurology</i> , 2023, 25, 121-133.	0.7	1
399	Tau positron emission tomography in tauopathies: A narrative review. <i>Precision and Future Medicine</i> , 2023, 7, 7-24.	0.5	0
400	Genetic Phenotypes of Alzheimer's Disease: Mechanisms and Potential Therapy. <i>Phenomics</i> , 2023, 3, 333-349.	0.9	5
401	A global view of the genetic basis of Alzheimer disease. <i>Nature Reviews Neurology</i> , 2023, 19, 261-277.	4.9	19
402	Lowering levels of reelin in entorhinal cortex layer II-neurons results in lowered levels of intracellular amyloid- β . <i>Brain Communications</i> , 2023, 5, .	1.5	3
403	Geroprotective interventions in the 3xTg mouse model of Alzheimer's disease. <i>GeroScience</i> , 0, , .	2.1	2
412	Parkinsonism in complex neurogenetic disorders: lessons from hereditary dementias, adult-onset ataxias and spastic paraplegias. <i>Neurological Sciences</i> , 0, , .	0.9	0
422	Etiology, pathogenesis of Alzheimer's disease and amyloid beta hypothesis. , 2024, , 1-11.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------